search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


MR CLEAN: a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in The Netherlands.


- candidate number5714
- NTR NumberNTR1804
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR7-mei-2009
- Secondary IDs2008T030 NHS (Netherlands Heart Foundation)
- Public TitleMR CLEAN: a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in The Netherlands.
- Scientific TitleMR CLEAN: a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in The Netherlands.
- ACRONYMMR CLEAN
- hypothesisThe null hypothesis for this study is that endovascular treatment for acute ischemic stroke with onset of less than six hours in patients with a symptomatic intracranial proximal arterial occlusion, leads to a similar distribution of functional outcomes as standard treatment.
- Healt Condition(s) or Problem(s) studiedAcute ischaemic stroke, Intracranial arterial occlusion
- Inclusion criteria1. A clinical diagnosis of acute stroke, with a deficit on the NIH stroke scale of > 2 points;
2. CT or MRI scan rules out intracranial hemorrhage;
3. Intracranial arterial occlusion of the distal intracranial carotid artery or middle (M1/M2) or anterior (A1/A2) cerebral artery, demonstrated with CTA, MRA, DSA or transcranial Doppler/duplex (TCD);
4. The possibility to start treatment within 6 hours from onset;
5. Informed consent given;
6. Age 18 or over.
- Exclusion criteria1. Cerebral infarction within the previous 6 weeks;
2. History of intracerebal hemorrhage;
3. Severe head injury the previous 4 weeks;
4. Major surgery, gastrointestinal bleeding or urinary tract bleeding within 2 weeks;
5. Arterial blood pressure > 185/110 mmHg;
6. Blood glucose < 2.7 or > 22.2 mmol/l;
7. Platelet count <90 x 10*9/L;
8. APTT>50 s or INR >1.7;
9. Intravenous treatment with thrombolytic therapy in a dose exceeding 0.9 mg/kg rtPA or 90 mg.
- mec approval receivedno
- multicenter trialyes
- randomisedyes
- masking/blindingSingle
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-jan-2010
- planned closingdate1-jan-2015
- Target number of participants500
- InterventionsIntra-arterial treatment (rtPA and/or mechanical thrombectomy) versus no intra-arterial treatment. The treatment is provided in addition to best medical management, including intravenous thrombolysis.
- Primary outcomeThe score on the modified Rankin scale at 90 days.
- Secondary outcomeImaging parameters:
1. Vessel recanalization at 24-48 hours after treatment, assessed by CTA or MRA;
2. Infarct size at 24-48 hours assessed by CT;
3. (A-)symptomatic intracerebral hemorrhage at 24-48 hours assessed by CT.

Clinical parameters:
1. Mortality at 1 week and at 90 days;
2. The score on the NIH stroke scale at 24-48 hours after treatment;
3. The score on the NIH stroke scale at 1 week or at discharge.

Functional outcome:
1. Score on the EQ5D at 90 days;
2. Barthel index at 90 days;
3. Score on the Academic Linear Disability Scale at 90 days.
- TimepointsFirst patient in: april 2010.
Last patient out: July 2014.
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESMD P. Fransen
- CONTACT for SCIENTIFIC QUERIESDr. D.W.J. Dippel
- Sponsor/Initiator Erasmus Medical Center, Academic Medical Center (AMC), Amsterdam, Academic Hospital Maastricht (AZM)
- Funding
(Source(s) of Monetary or Material Support)
Dutch Heart Foundation (Nederlandse Hartstichting)
- PublicationsN/A
- Brief summaryEndovascular treatment increases the likelihood of recanalization in patients with acute ischemic stroke caused by proximal intracranial arterial occlusion. The purpose of the Multicenter Randomized Clinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN) is to assess the safety and effect on functional outcome of endovascular treatment in such patients. DESIGN:
MR CLEAN is a pragmatic phase III multicenter randomized clinical trial with blind outcome assessment. We compare endovascular treatment (intra-arterial thrombolysis, mechanical thrombectomy or both) with no treatment, against a background of optimal medical management, which may include intravenous alteplase. Patients should have a clinical diagnosis of acute ischemic stroke, confirmed by MRI or CT, an NIHSS score of 2 points or more, a relevant intracranial arterial occlusion, demonstrated by CTA, MRA or TCD and the possibility to start endovascular treatment within 6 hours after stroke onset. The exact choice of endovascular treatment modality for each patient is left to the discretion of the local investigator and treating physicians. The steering committee will release recommendations and guidelines for treatment and selection of patients in the study.
STUDY OUTCOMES:
The primary outcome is the score on the modified Rankin scale 3 months after inclusion in the study. Secundary outcomes are the NIHSS score at 48 hours, vessel patency, score on the Barthel index, and the occurrence of major bleeding. Randomization will be stratified for treatment with iv rtPA, stroke severity according to the National Institutes of Health Stroke Scale, intended mechanical thrombectomy and center. We will estimate the effect of treatment by means of the sliding dichotomy approach, which considers the whole range of the mRS. In total, 500 patients will be included.
DISCUSSION:
MR CLEAN is a pragmatic trial. Centers from other countries than the Netherlands are welcome to join the study. Inclusion of patients will take 4 years, and starts early in 2010.
- Main changes (audit trail)
- RECORD7-mei-2009 - 30-sep-2009


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl